#BIO22: Are biotech buy­outs fi­nal­ly com­ing in­to vogue? Here's what to look for in H2 M&A

If you want an idea of the kind of biotech M&A deals to ex­pect in H2, look at the re­cent spate of buy­outs.

End­points News talked with a phar­ma in­vest­ment banker, an ex­pe­ri­enced deal­mak­er, a fi­nance pro­fes­sor at MIT and a top an­a­lyst to find out what’s cen­ter stage these days in the M&A scene, as the bear mar­ket mauls biotech stocks and eras­es fol­low-on op­por­tu­ni­ties.

The trend of ac­quir­ing late-stage biotech com­pa­nies is ex­pect­ed to con­tin­ue in­to the sec­ond half of the year, sources told End­points. But while there are signs of hope for a quick­ened pace of M&A — Bris­tol My­ers Squibb’s an­nounce­ment it would ac­quire clin­i­cal-stage pre­ci­sion on­col­o­gy com­pa­ny Turn­ing Point Ther­a­peu­tics for a 122% pre­mi­um over the pre­vi­ous clos­ing price made some ques­tion if the bear mar­ket may fi­nal­ly be over — there aren’t any guar­an­tees.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER